Sharon Jackson, APRN
Family · Baton Rouge, LANPI 1043566383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 841 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 841 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$1K
- Acadia Pharmaceuticals Inc$1K
- Amgen$1K
- Novartis$963
- Sanofi$759
- plus $6K from 43 others
What the payments were for
- Speaking & faculty fees$2001%
- Food & beverage$14,46698%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,783 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 12 | $378,714 |
| Kesimpta PenOfatumumab | 33 | $323,000 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 24 | $281,898 |
| NuplazidPimavanserin Tartrate | 37 | $214,835 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 30 | $165,726 |
| Emgality SyringeGalcanezumab-Gnlm | 36 | $42,574 |
| NuedextaDextromethorphan Hbr/Quinidine | 40 | $42,266 |
| Emgality PenGalcanezumab-Gnlm | 31 | $21,596 |
| Glatiramer Acetate | 15 | $21,204 |
| Oxtellar XrOxcarbazepine | 21 | $20,791 |
| UbrelvyUbrogepant | 15 | $17,601 |
| FycompaPerampanel | 11 | $15,502 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $14,767 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $13,345 |
| Levetiracetam | 131 | $3,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $1,250 | $281,89824 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,248 | $214,83537 claims |
| Grifols USA, LLCGamunex-C | $90 | $165,72630 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $43 | $42,26640 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $139 | $20,79121 claims |
| AbbVieUbrelvy | $3,190 | $17,60115 claims |
| Eisai Inc.Fycompa | $174 | $15,50211 claims |
| Upsher-smith Laboratories LLCTopiramate | $25 | $66957 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $86 | $63911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Baton Rouge
- Elidia DewittBaton Rouge$108K
- Ghenet GhebretatiosBaton Rouge$91K
- Heather SullivanBaton Rouge$32K
- Randee KidderBaton Rouge$30K
- Dionne BellBaton Rouge$24K
- Jennifer LittleBaton Rouge$21K
- Tracy ParkerBaton Rouge$19K
- Kristen VillarBaton Rouge$18K
- Gloria MarchandBaton Rouge$14K
- Stephanie ThomasBaton Rouge$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.